Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Bioorg Med Chem Lett ; 29(7): 929-932, 2019 04 01.
Article in English | MEDLINE | ID: mdl-30773432

ABSTRACT

In the course of a programme aimed at identifying Nurr1/NOT agonists for potential treatment of Parkinson's disease, a few hits from high throughput screening were identified and characterized. A combined optimization pointed to a very narrow and stringent structure activity relationship. A comprehensive program of optimization led to a potent and safe candidate drug displaying neuroprotective and anti-inflammatory activity in several in vitro and in vivo models.


Subject(s)
Neuroprotective Agents/chemical synthesis , Neuroprotective Agents/pharmacology , Nuclear Receptor Subfamily 4, Group A, Member 2/metabolism , Parkinson Disease/drug therapy , Animals , Cell Line , Cricetinae , Drug Discovery , Gene Expression Regulation/drug effects , Homeodomain Proteins/metabolism , Interleukin-1beta/genetics , Interleukin-1beta/metabolism , Mice , Microglia/drug effects , Molecular Structure , Neurons/drug effects , Nuclear Receptor Subfamily 4, Group A, Member 2/genetics , Rats , Retinoid X Receptors/genetics , Retinoid X Receptors/metabolism
2.
Chemistry ; 18(14): 4337-44, 2012 Apr 02.
Article in English | MEDLINE | ID: mdl-22383395

ABSTRACT

An in-depth study of the cobalt-catalyzed [2+2+2] cycloaddition between yne-ynamides and nitriles to afford aminopyridines has been carried out. About 30 nitriles exhibiting a broad range of steric demand and electronic properties have been evaluated, some of which open new perspectives in metal-catalyzed arene formation. In particular, the use of [CpCo(CO)(dmfu)] (dmfu=dimethyl fumarate) as a precatalyst made possible the incorporation of electron-deficient nitriles into the pyridine core. Modification of the substitution pattern at the yne-ynamide allows the regioselectivity to be switched toward 3- or 4-aminopyridines. Application of this synthetic methodology to the construction of the aminopyridone framework using a yne-ynamide and an isocyanate was also briefly examined. DFT computations suggest that 3-aminopyridines are formed by formal [4+2] cycloaddition between the nitrile and the intermediate cobaltacyclopentadiene, whereas 4-aminopyridines arise from an insertion pathway.


Subject(s)
Alkynes/chemistry , Amides/chemistry , Aminopyridines/chemical synthesis , Cobalt/chemistry , Nitriles/chemistry , Pyridones/chemical synthesis , Aminopyridines/chemistry , Catalysis , Cyclization , Molecular Structure , Pyridones/chemistry , Stereoisomerism
3.
Org Lett ; 13(8): 2030-3, 2011 Apr 15.
Article in English | MEDLINE | ID: mdl-21413688

ABSTRACT

Bimolecular cobalt-catalyzed [2 + 2 + 2] cycloadditions between yne-ynamides and nitriles afford bicyclic 3- or 4-aminopyridines in up to 100% yield. The high regioselectivity observed depends on the substitution pattern at the starting ynamide. Aminopyridines bearing TMS and Ts groups are efficiently deprotected in an orthogonal fashion.


Subject(s)
4-Aminopyridine/chemistry , Aminopyridines/chemistry , Bridged Bicyclo Compounds, Heterocyclic/chemistry , Cobalt/chemistry , Catalysis , Models, Molecular , Molecular Structure , Stereoisomerism
4.
CNS Drug Rev ; 9(1): 3-20, 2003.
Article in English | MEDLINE | ID: mdl-12595909

ABSTRACT

SL651498 (6-fluoro-9-methyl-2-phenyl-4-(pyrrolidin-1-yl-carbonyl)-2,9-dihydro-1H-pyrido[3,4-b]indol-1-one) was identified as a drug development candidate from a research program designed to discover subtype-selective GABA(A) receptor agonists for the treatment of generalized anxiety disorder and muscle spasms. The drug displays high affinity for rat native GABA(A) receptors containing alpha(1) (K(i) = 6.8 nM) and alpha(2) (K(i) = 12.3 nM) subunits, and weaker affinity for alpha5-containing GABA(A) receptors (K(i) = 117 nM). Studies on recombinant rat GABA(A) receptors confirm these findings and indicate intermediate affinity for the alpha(3)beta(2)gamma(2) subtype. SL651498 behaves as a full agonist at recombinant rat GABA(A) receptors containing alpha(2) and alpha(3) subunits, and as a partial agonist at recombinant GABA(A) receptors expressing alpha(1) and alpha(5) subunits. SL651498 produced anxiolytic-like and skeletal muscle relaxant effects qualitatively similar to those of benzodiazepines (BZs) [minimal effective dose (MED): 1 to 10 mg/kg, i.p. and 3 to 10 mg/kg, p.o.]. However, unlike these latter drugs, SL651498 induced muscle weakness, ataxia or sedation at doses much higher than those having anxiolytic-like activity (MED: 30 to 100 mg/kg, i.p. or p.o.). Moreover, in contrast to BZs, SL651498 did not produce tolerance to its anticonvulsant activity or physical dependence. It was much less active than BZs in potentiating the depressant effects of ethanol or impairing cognitive processes in rodents. The differential profile of SL651498 as compared to BZs may be related to its selective efficacy at the alpha(2)- and alpha(3)-containing GABA(A) receptors. This suggests that selectively targeting GABA(A) receptor subtypes can lead to drugs with increased clinical specificity. SL651498 represents a promising alternative to agents currently used for the treatment of anxiety disorders and muscle spasms without the major side effects seen with classical BZs.


Subject(s)
Anxiety Disorders/drug therapy , GABA-A Receptor Agonists , Indoles/pharmacology , Indoles/therapeutic use , Pyrroles/pharmacology , Pyrroles/therapeutic use , Spasm/drug therapy , Amnesia, Anterograde/chemically induced , Animals , Ataxia/chemically induced , Central Nervous System/drug effects , Discrimination Learning/drug effects , Discrimination, Psychological/drug effects , Drug Interactions , Drug Tolerance , Ethanol/pharmacology , GABA Agonists/administration & dosage , GABA Agonists/adverse effects , GABA Agonists/chemistry , GABA Agonists/pharmacology , GABA Agonists/therapeutic use , Indoles/adverse effects , Indoles/chemistry , Mice , Pyrroles/adverse effects , Pyrroles/chemistry , Rats , Substance-Related Disorders/etiology
SELECTION OF CITATIONS
SEARCH DETAIL
...